Network Pharmacology Elucidates SFI's Anti-Glioma Mechanism via SRC/PI3K/AKT

Study Background and Research Question

Gliomas represent 30–50% of all primary brain tumors and are characterized by aggressive proliferation, high invasiveness, and poor patient prognosis, with median survival often under 17 months. Despite advances in surgery, radiotherapy, and chemotherapy, therapeutic outcomes remain unsatisfactory, prompting continued search for more effective interventions. Traditional Chinese medicine formulations, such as Shenqi Fuzheng injection (SFI), are widely used as adjuvant therapies in oncology, but their molecular mechanisms in glioma treatment have not been fully clarified. The central research question addressed in this recent study is: How does SFI exert its anti-glioma effects, and which signaling pathways and molecular targets are involved in its action?

Key Innovation from the Reference Study

The primary innovation of the study lies in its integrative application of network pharmacology and experimental validation to decipher the mechanistic basis of SFI's anti-glioma efficacy. Rather than focusing on isolated components or single targets, the research systematically identifies the multi-targeted nature of SFI and pinpoints the SRC/PI3K/AKT signaling pathway as a central mediator. This systems-level approach not only clarifies SFI's impact on glioma cell proliferation and migration but also provides a rational basis for exploiting this pathway in anti-angiogenic compound discovery and tumor inhibition strategies.

Methods and Experimental Design Insights

The study began by screening potential targets of SFI for glioma intervention using established network pharmacology methodologies. Candidate targets and active components were identified through data mining, leveraging multiple databases and literature sources, including PubMed and Web of Science. A total of 26 major active compounds from SFI were catalogued, with 110 targets enriched and 79 targets found to overlap between SFI and glioma tissues.

Experimental validation was conducted in vitro using human glioma cell lines (U87 and T98G) and in vivo in a mouse xenograft model employing GL261 cells. The in vitro workflow included CCK-8 cell viability assays, EdU incorporation for proliferation, plate cloning, scratch and Transwell migration assays, immunofluorescence for EMT markers, flow cytometry for cell cycle analysis, and Western blotting for pathway interrogation. In vivo, tumor growth and histopathological changes were assessed using HE staining and immunohistochemistry on subcutaneous tumor tissues.

Protocol Parameters

• Cell Culture: Maintain U87 and T98G glioma cells under standard conditions; specific SFI concentrations for in vitro assays were optimized to observe dose-dependent effects on proliferation and migration.
• Cell Proliferation Assays: Apply CCK-8 and EdU incorporation assays after 24–72 h SFI exposure to detect changes in growth rates.
• Migration and Invasion: Implement scratch and Transwell assays post-SFI treatment, monitoring wound closure and transmembrane migration, respectively.
• Cell Cycle Analysis: Use flow cytometry to quantify S-phase arrest following SFI administration.
• In Vivo Model: Inject GL261 cells subcutaneously into C57BL/6 mice, treat with SFI, and evaluate tumor volume and histology after specified intervals (typically 2–3 weeks).

Core Findings and Why They Matter

Network analysis revealed that the SRC/PI3K/AKT signaling cascade is a primary conduit for SFI's anti-glioma activity. Functional assays showed that SFI inhibited proliferation and induced S-phase cell cycle arrest in both U87 and T98G lines. Furthermore, SFI suppressed cell migration and invasion, which correlated with downregulation of epithelial-mesenchymal transition (EMT) markers. In vivo, SFI administration significantly reduced tumor growth in a mouse model, supporting its anti-tumor potential. These findings establish a mechanistic link between SFI's traditional clinical use and its molecular action, particularly through targeting the SRC/PI3K/AKT pathway—a pathway also implicated in tumor angiogenesis and metastasis.

This mechanistic clarity is crucial for tumor angiogenesis research, as the SRC/PI3K/AKT axis is integrally involved in processes such as endothelial cell migration, survival, and vascular growth. By illuminating how SFI interferes with this pathway, the study provides a foundation for the rational development of new angiogenesis inhibitors and anti-metastatic agents.

Comparison with Existing Internal Articles

Several internal resources contextualize and complement these findings. For example, "Network Pharmacology Uncovers SFI's Anti-Glioma Mechanisms via SRC/PI3K/AKT" and "Network Pharmacology Reveals SFI's Anti-Glioma Mechanism via SRC/PI3K/AKT" both reinforce the mechanistic importance of the SRC/PI3K/AKT pathway, underscoring SFI's dual anti-angiogenic and anti-metastatic effects in glioma models. These articles further detail the systems pharmacology approach and experimental validation, providing workflow guidance for researchers seeking to replicate or expand upon these results.

In the broader context of anti-angiogenic compound evaluation, articles such as "AAL-993: Precision VEGF Receptor Inhibitor for Tumor Angiogenesis" and "AAL-993: Systems-Level Insights for Anti-Angiogenic Research" discuss the utility of highly selective VEGF receptor inhibitors in dissecting the functional consequences of angiogenic pathway modulation. These comparisons highlight the complementary value of both multi-component herbal formulations and targeted small-molecule tools in tumor angiogenesis research.

Limitations and Transferability

While the study provides compelling evidence for SFI's anti-glioma effects and elucidates a central molecular pathway, several limitations merit consideration. The heterogeneity and complexity of SFI's herbal composition pose reproducibility challenges, and mechanistic conclusions are primarily limited to preclinical models. Translation to clinical settings will require further investigation of pharmacokinetics, standardization, and potential interactions with existing chemotherapeutic regimens. Additionally, while the SRC/PI3K/AKT pathway is highly relevant in glioma biology, its role in other tumor types and vascular microenvironments should be validated with additional experimental systems.

Research Support Resources

For researchers aiming to model anti-angiogenic mechanisms or benchmark new compounds alongside established inhibitors, the selective VEGF receptor inhibitor AAL-993 (SKU C3730, APExBIO) offers a robust tool for both in vitro and in vivo angiogenesis studies. AAL-993’s potency against VEGFR-1, VEGFR-2, and VEGFR-3, as detailed in the product information, enables precise dissection of VEGF-mediated signaling and tumor vascularization. Integrating such defined inhibitors can complement systems pharmacology approaches exemplified by SFI studies, supporting rigorous experimental design in tumor angiogenesis and metastasis research.